Boston Scientific Lowers Full-Year Outlook Despite Q1 Beat
Boston Scientific (BSX) shares fell in premarket trading after the company cut its full-year revenue growth outlook to 7.0% to 8.5% YoY for 2026, despite reporting better-than-expected Q1 2026 results. The move reflects cautious expectations for the remainder of the year.
Tickers: $BSX
Topics: Boston Scientific Q1 2026 earnings revenue guidance stock price movement